Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10056658 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL3313146 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL7636794 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL7034253 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL24584612 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL20524278 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL23330709 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL7034256 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL13621664 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL7153175 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537134-B1 | PROCESS FOR PRODUCING A RIBOFURANOSE | HOFFMANN LA ROCHE (CH) | 2006-04-05 | — | — | EP | claimed |
| EP-1537134-A1 | PROCESS FOR PRODUCING A RIBOFURANOSE | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | claimed |
| WO-2004018492-A1 | PROCESS FOR PRODUCING A RIBOFURANOSE | F. HOFFMANN-LA-ROCHE AG (CH) | 2004-03-04 | — | — | WO | claimed |
| US-20260108495-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097018-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260076946-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-19 | — | — | US | disclosed |
| US-20260076945-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-19 | — | — | US | disclosed |
| US-12527771-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250332146-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICALS CO (JP) | 2025-10-30 | — | — | US | disclosed |
| US-12377078-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| US-5998605-A | Antiviral benzimidazole nucleoside analogues and method for their preparation | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0769017-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377078-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TYMS, TYMP, DUT | CYP2D6 725/4885THRB 3396/4885HSD17B10 2347/4885 |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | CYP2D6 1619/4885THRB 766/4885HSD17B10 3044/4885 |
| US-20260076946-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TPMT, MPST, PCMT1 | CYP2D6 888/4885THRB 4388/4885HSD17B10 1911/4885 |
| US-12527771-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | IRF3, RPL12, MCM4 | CYP2D6 1585/4885THRB 2927/4885HSD17B10 3744/4885 |
| US-20260097018-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TPMT, PCMT1, RPL7 | CYP2D6 274/4885THRB 4605/4885HSD17B10 2171/4885 |
| US-20250332146-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | MAVS, SARS1, POLRMT | CYP2D6 1791/4885THRB 4528/4885HSD17B10 1335/4885 |
| US-20260076945-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | PCMT1, MPST, TPMT | CYP2D6 452/4885THRB 4652/4885HSD17B10 1746/4885 |
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | CYP2D6 1235/4885THRB 4729/4885HSD17B10 2890/4885 |
| US-20260108495-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO | HYOU1, CYP2F1, HAVCR2 | CYP2D6 89/4885THRB 3085/4885HSD17B10 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.